Profile for Spain Patent: 2383713

US Patent Family Members and Approved Drugs for Spain Patent: 2383713

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 17, 2029	Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate
	Apr 17, 2029	Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate

What Is the Scope of ES2383713 and How Does It Sit in the Spain Patent Landscape?

Last updated: April 25, 2026

What does ES2383713 cover, and what is the claim scope?

No complete, claim-level dataset for ES2383713 is available in the provided material. Without the published description and claims (and the authoritative bibliographic record for the Spanish publication), a complete and accurate claim-scope analysis cannot be produced.

What is the patent landscape around ES2383713 in Spain?

No verifiable landscape facts can be produced from the provided material. A Spain-only landscape requires at minimum: (i) the publication number’s legal family, (ii) priority and filing dates, (iii) assignee/holder, (iv) CPC/IPC classification, and (v) claim themes from the published claims. None of these inputs are present here, so no precise mapping of overlapping filings, freedom-to-operate risks, or expiry timelines can be stated.

What claim themes would need to be checked for competitive design-around and FTO?

Not produced. Claim-level analysis is not possible without the claims text for ES2383713. A correct FTO and design-around assessment depends on identifying each independent claim and its essential limitations (active ingredient, salt/form, polymorph, dosage form, dosage regimen, process steps, patient population, biomarkers, combination partners, and any functional limitations).

What does the legal status imply for Spanish enforcement and expiry?

Not produced. Legal status (in force, terminated, lapsed, opposition history, limitation, or surrender) depends on the authoritative Register record for ES2383713 and related family members. Those facts are not included in the provided material.

---

Key Takeaways

• Scope and claim coverage for ES2383713 cannot be determined from the provided input.
• A Spain landscape cannot be mapped without bibliographic and claim text anchors for ES2383713.
• No reliable conclusions on overlap, FTO exposure, or expiry can be issued without the authoritative publication record and claims.

---

FAQs

1) Can you summarize the independent claims of ES2383713?

No. The published claims text is not provided.

2) What is the likely patent term and expiry in Spain for ES2383713?

Not determinable from the provided material because term and any adjustments depend on priority date, filing date, regulatory extensions (if any), and the legal status record.

3) Which entities are the assignees and how many family members exist for ES2383713?

Not determinable from the provided material.

4) Are there close citations or forward patents in Spain that overlap ES2383713?

Not determinable without the bibliographic record, classification codes, and publication family links.

5) How would you assess design-around strategies for ES2383713?

A design-around assessment must map claim limitations to product attributes, but ES2383713 claims are not available in the provided input.

---

References

No sources were provided in the prompt to cite.